Ocular hypertension and intravitreal steroids injections, update in 2023. French guidelines of the French glaucoma society and the French ophthalmology society

J Fr Ophtalmol. 2023 Jun 9:S0181-5512(23)00246-2. doi: 10.1016/j.jfo.2023.05.001. Online ahead of print.ABSTRACTThese guidelines are a consensus of French glaucoma and retina experts on the management of ocular hypertension (OHT) observed in a third of the cases after corticosteroid implant intravitreal injections. They update the first guidelines published in 2017. Two implants are marketed in France: the dexamethasone implant (DEXi) and the fluocinolone acetonide implant (FAci). It is essential to assess the pressure status before injecting a patient with a corticosteroid implant. A molecule-specific monitoring of the intraocular pressure is needed throughout the follow-up and at the time of reinjections. Real-life studies have allowed optimizing the management algorithm by significantly increasing the safety of these implants. Corticosteroid testing with DEXi should be performed before switching to FAci to optimize pressure tolerance of FAci. Beyond topical hypotensive treatments, selective laser trabeculoplasty may be considered in the therapeutic arsenal for the management of steroid-induced OHT and subsequent injections.PMID:37302867 | DOI:10.1016/j.jfo.2023.05.001

Source: Journal Francais d Ophtalmologie - June 11, 2023 Category: Opthalmology Authors: C Dot M Poli F Aptel A Labbe L Kodjikian S Baillif B Bodaghi P Denis Source Type: research